Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
Status:
Completed
Trial end date:
2018-03-22
Target enrollment:
Participant gender:
Summary
This open label study was designed to evaluate Lapatinib effect on incidence of brain
metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior
taxanes or anthracyclines.